Cash PositionManagement anticipates that the cash position is strong, with approximately $246 million in cash, cash equivalents, restricted cash, and fixed-term deposits.
Clinical TrialsCellectis is on track to initiate a pivotal Phase 2 trial for lasme-cel in relapsed/refractory B-ALL.
PartnershipsCellectis is making substantial progress across its clinical programs following a pipeline overhaul and strategic investment by AstraZeneca.